Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Emergency Pharmacist Safety Study

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
University of Rochester
ClinicalTrials.gov Identifier:
NCT00382434
First received: September 27, 2006
Last updated: January 13, 2010
Last verified: January 2010
  Purpose

The Emergency Department (ED) is a unique environment in medicine, and many safety mechanisms used in other hospital settings cannot be applied in the ED. For example, clinical pharmacists have traditionally provided extra layers of protection to hospital inpatients by cross-checking provider orders for appropriate dosing, contraindications, and interactions. Because medications in the ED must be accessed immediately and are often one-time doses, the use of central pharmacy services would introduce an unacceptable delay to the administration of medication. Although some hospitals have programs in place in which a pharmacist responds to the ED for cardiac arrests or trauma team activations, few have reported programs which involve a clinical pharmacist assigned exclusively to the emergency department. Nonetheless, published reports have asserted that ED-based pharmacists can increase patient safety. Although this concept appears logical, no study has attempted to show that these programs reduce potential adverse drug events in the ED. We propose to implement and optimize an ED Pharmacist (EDP) program as a safe practice intervention in a large ED. The hospital has provided funding for two permanent full time positions starting at the beginning of the award period. In the initial phase interviews of physicians, nurses, pharmacists, and patients will be conducted and the results will be used to optimize the EDP role. A large-scale chart review study will then be conducted to evaluate whether there is a reduction in frequency of potential and adverse drug events during times that the EDP is on duty. Staff perceptions of the effectiveness of this program will also be evaluated. The overall goal of this initiative is to create an effective EDP program that will decrease the rate of adverse drug events in ED patients, and to create a "toolkit" to facilitate the introduction of similar programs into other EDs. This toolkit will include a description of the formal, optimized role of the EDP, challenges and solutions in implementation, and evidence to support the efficacy of such a program.


Condition Intervention
Adverse Drug Event, Potential Adverse Drug Event, and Quality Measures
Procedure: presence of an emergency pharmacist in the ED

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: The ED Pharmacist as a Safety Measure in Emergency Medicine

Resource links provided by NLM:


Further study details as provided by University of Rochester:

Enrollment: 10224
Study Start Date: August 2005
Study Completion Date: December 2006
Groups/Cohorts Assigned Interventions
EPh Present
the emergency pharmacist is present in the ED when the medical care is provided
Procedure: presence of an emergency pharmacist in the ED

  Eligibility

Genders Eligible for Study:   Both
Sampling Method:   Probability Sample
Study Population

emergency department patients

Criteria

Inclusion Criteria:

  • pediatric (less than 19), geriatric (>64), or critically ill (all ages)

Exclusion Criteria:

  • investigator involved or incomplete chart
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00382434

Locations
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Investigators
Principal Investigator: Rollin J Fairbanks, MD, MS University of Rochester
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00382434     History of Changes
Other Study ID Numbers: 1U18HS015818, RSRB #11834
Study First Received: September 27, 2006
Last Updated: January 13, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of Rochester:
emergency pharmacist
emergency medicine
emergency department
medical error
adverse event
pharmacist
patient safety

Additional relevant MeSH terms:
Drug-Related Side Effects and Adverse Reactions
Emergencies
Chemically-Induced Disorders
Disease Attributes
Pathologic Processes

ClinicalTrials.gov processed this record on November 20, 2014